ADC Therapeutics releases preliminary 2024 ZYNLONTA sales and expense data at JPM conference

ADC Therapeutics SA

2024-FY EPS reported -$1.62 revenue$70,837,000

Preliminary ZYNLONTA net sales and FY2024 expenses disclosed at JPMorgan Healthcare Conference; no specific figures in filing.
Forward-looking statements reference expected cash runway into mid-2026 and potential to grow ZYNLONTA revenue.
Presentation highlights pipeline including LOTIS 5, LOTIS 7, ADCT-602, and exatecan-based solid tumor platform.
ZYNLONTA is approved for relapsed/refractory large B-cell lymphoma after two prior therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.